A happy medium for stem cells? Irvine Scientific launches GMP xeno-free offering

By Dan Stanton

- Last updated on GMT

Image: iStock/Sage78
Image: iStock/Sage78
Xeno-free and cGMP-manufactured media are highly desired by cell therapy developers, says Irvine Scientific as it launches a medium for hematopoietic stem and progenitor cells (HSPCs).

According to Irvine Scientific, its latest serum-free, xeno-free PRIME-XV basal medium supports the robust expansion of hematopoietic progenitors while maintaining their multipotency, and is now available for customers working with HSPCs.

HSPCs come from blood or bone marrow of donors and are rare (just 1 in 100,000 in peripheral blood cells and 1 in 10,000 in bone marrow), so growing sufficient numbers for therapeutic purposes while maintaining progenitor cell properties is a challenge.

“This new product optimises the cell yield by enhancing cell proliferation without losing the identity of hematopoietic progenitors, so one would get the most numbers of desired cell types suitable for transplantation,”​ Irvine product line manager Duncan Liew told Biopharma-Reporter.

This is the latest in Irvine’s xeno-free range of medium, after the Californian-based firm launched a similar offering for neural cells last July​ and an animal-free cell growth medium for T cell cultures in January​.

“The use of xeno-free media is critical to eliminate the risk of contamination from animal products, such as FBS [fetal bovine serum], and to provide lot-to-lot consistency, ensuring optimal cell yield and good quality cell cultures,”​ Lieuw said.

“Many cell-based therapies have already moved towards the use of serum-free and xeno-free media.”

He added there is no one size fits all solution for cell-based therapies. “All are depending on the applications and cell types. For example, some cells are grown on monolayer, some could be grown in suspension and such large scale expansion could require the use of bioreactors.”

But the PRIME-XV offering does offer the advantage that it is produced under current good manufacturing practice (cGMP). This is “now highly desired starting from preclinical and early stages of clinical trials,”​ among customers, Lieuw said.

“This new medium is cGMP-manufactured and will come with a Drug Master File registration with FDA – another benefit we offer compared to many other competitors media!”

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars